Dupilumab maintenance therapy in an asthmatic patient with coronavirus disease 2019 pneumonia

Allergol Int. 2021 Apr;70(2):274-276. doi: 10.1016/j.alit.2020.10.005. Epub 2020 Nov 7.

Authors

Naoya Tanabe¹, Hisako Matsumoto², Satoshi Hamada³, Isao Ito¹, Toyohiro Hirai¹

Affiliations

¹ Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
² Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Electronic address: hmatsumo@kuhp.kyoto-u.ac.jp.
³ Department of Advanced Medicine for Respiratory Failure, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anti-Asthmatic Agents / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Asthma / complications
Asthma / drug therapy*
COVID-19 / complications*
Humans
Male
Middle Aged

Substances

Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
dupilumab